Gilead Sciences Reports Five-Year ZUMA-1 Data for Yescarta in DLBCL

Gilead Sciences today presented five-year follow-up data from the ZUMA-1 trial evaluating Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma. The data showed that 31% of patients remained in ongoing remission at five years, with the majority of long-term responders achieving complete remission after a single infusion.